Literature DB >> 23314484

Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells.

Dick Pluim1, Kim A A Schilders, Bart A W Jacobs, Daniëlle Vaartjes, Jos H Beijnen, Jan H M Schellens.   

Abstract

A simple, selective, and sensitive method utilizing tritium ((3)H) release from (3)H-deoxyuridine 5'-monophosphate (dUMP) substrate for accurate and precise determination of the low basal thymidylate synthase activity (TSA) in normal healthy peripheral blood mononuclear cells (PBMCs) was developed and validated. The method is based on the removal of the remaining substrate after the TSA reaction by absorption onto activated carbon and measurement of the supernatant fluid by liquid scintillation counting. The method background was substantially decreased by using lyophilized substrate and optimized binding conditions of remaining substrate onto carbon after TSA reaction. The concentration of cofactor N (5),N (10) methylene-(6R,S)-tetrahydrofolate was increased to obtain maximal TSA. Method sensitivity was further increased by omission of ethylenediaminetetraacetic acid from the reaction mix and by using longer reaction times. The validation parameters included specificity, linearity, sensitivity, precision, and stability. The lower limit of quantification was 25 μg PBMC cytosolic lysate, which released 1.4 pmol (3)H/h. TSA was stable in PBMC pellets stored for 6 months at -80 °C. The applicability of the method was demonstrated by the successful determination of TSA in PBMC cytosolic lysates from ten healthy volunteers with and without the specific TSA inhibitor FdUMP.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23314484     DOI: 10.1007/s00216-012-6676-1

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  3 in total

1.  Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

Authors:  Bart A W Jacobs; Maarten J Deenen; Dick Pluim; J G Coen van Hasselt; Martin D Krähenbühl; Robin M J M van Geel; Niels de Vries; Hilde Rosing; Didier Meulendijks; Artur M Burylo; Annemieke Cats; Jos H Beijnen; Alwin D R Huitema; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

2.  Dihydrofolate Reductase/Thymidylate Synthase Fine-Tunes the Folate Status and Controls Redox Homeostasis in Plants.

Authors:  Vera Gorelova; Jolien De Lepeleire; Jeroen Van Daele; Dick Pluim; Coline Meï; Ann Cuypers; Olivier Leroux; Fabrice Rébeillé; Jan H M Schellens; Dieter Blancquaert; Christophe P Stove; Dominique Van Der Straeten
Journal:  Plant Cell       Date:  2017-09-22       Impact factor: 11.277

3.  Phase I pharmacological study of continuous chronomodulated capecitabine treatment.

Authors:  Jeroen Roosendaal; Bart A W Jacobs; Dick Pluim; Hilde Rosing; Niels de Vries; Erik van Werkhoven; Bastiaan Nuijen; Jos H Beijnen; Alwin D R Huitema; Jan H M Schellens; Serena Marchetti
Journal:  Pharm Res       Date:  2020-05-07       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.